"Alternative to x-ray" claim allows clinicians to adopt new
standard of catheter location technology
LIMERICK, Pa., Mar 03, 2011 (BUSINESS WIRE) --
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technology products, today announced that its VasoNova Inc. subsidiary
has received 510(k) clearance from the U.S. Food and Drug Administration
(FDA) to market the company's VPS(TM) peripherally inserted central
catheter tip location technology as an alternative to chest x-ray or
fluoroscopy in adult patients when the guidance indicator shows a blue
bullseye.
Currently, after most central venous catheters are placed, the correct
location of the implanted catheter needs to be confirmed by chest x-ray,
a process that is costly, time consuming, often repeated because of
inaccuracy and which exposes the patient to radiation.
"VasoNova's VPS(TM) system is a market-leading central venous catheter
navigation technology. This clearance puts us in a strong competitive
position and offers the potential to establish a new standard of care in
catheter placement," commented Benson Smith, Teleflex Chairman,
President and CEO.
VasoNova VPS(TM) is the first system to use a combination of hemodynamic
and other biometric data to calculate precise tip location and to
communicate the position to the user via a simple graphical interface.
The system provides the clinician with the opportunity to place the
catheter correctly the first time, avoiding the need for confirmatory
chest x-ray where indicated. This provides benefits to the patient, the
care-giver and the health care system as a whole.
The VasoNova VPS(TM) system, comprising a portable console and a single-use
bio-sensor that is compatible with all major makes of central venous
catheters, is available now. The company began shipping product in
January to hospitals in the United States.
About Teleflex Incorporated
Teleflex Incorporated (NYSE: TFX) is a global provider of medical
technology products that enable healthcare providers to improve patient
outcomes, protect against infections and support patient and provider
safety. Teleflex, which employs approximately 12,500 people worldwide,
also has niche businesses that serve segments of the aerospace and
commercial markets with specialty engineered products. Additional
information about Teleflex can be obtained from the company's website at www.teleflex.com.
Forward-looking information
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
SOURCE: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Vice President Investor Relations
610-948-2836